News ArchivesRead News

Parkinson's extended-release drug fails to win FDA approval for U.S.

Tuesday January 22, 2013

www.nj.com - Impax Laboratories failed to win U.S. approval for a new version of an extended-release drug used to relieve spasms in patients with Parkinson’s disease.

The Food and Drug Administration requires a re-inspection of a plant involved in the development of the medicine called Rytary, which combines standard Parkinson’s medications in a new sustained release formulation, the Hayward, California-based company said today in a statement. A warning letter was issued in May 2011, Impax said.

“We will work with the FDA on the appropriate next steps for the Rytary application,” said Larry Hsu, president and CEO of Impax, in the statement. “We remain committed to resolving the warning letter and bringing this new treatment option to patients who are suffering from Parkinson’s disease.”

The medication would likely be used most among patients for whom the standard medicines, levodopa and carbidopa, have stopped working as reliably, said David Amsellem, an analyst with Piper Jaffray & Co. in New York. Rytary could generate peak sales of $200 million to $300 million, Amsellem said.

“A controlled-release product is something that has been elusive over the years,” Amsellem said in a telephone interview.

Impax, which specializes in controlled-release drugs, will develop and sell Rytary in the U.S. and Taiwan while GlaxoSmithKline, based in London, will market it in other regions throughout the world. Impax already markets a generic version of a longer-acting combination called Sinemet, sold by Merck & Co.

Merck’s Sinemet extended-release carbidopa-levodopa tablet received approval in 1991 though it’s not widely used, Amsellem said. People who use it are more likely to suffer impairment of voluntary movement than those who use the immediate-release version, according to the label for the medication.

Involuntary Movements

Patients with advanced Parkinson’s disease who used Rytary experienced a 34 percent decrease in the amount of time during waking hours when the medication wore off and involuntary muscle movements returned, the companies said in an August 2011 statement. This was compared with a decrease of 10 percent for those who used the immediate-release generic drugs combined with entacapone, a medicine that helps more of the other treatments reach the brain.

The starting point was 5.9 hours, improving to 3.8 hours of “off time” when Rytary wore off compared with 5.2 hours for the generics.

Parkinson’s is a progressive neurological disorder that causes body tremors, the loss of muscle control and impaired movement, according to the National Institutes of Health. There is no cure. A variety of medicines provide relief from symptoms for the estimated 10 million people worldwide with the disease.

Recent News

Oct 12 - Researchers identify immune gene that can prevent Parkinson's disease and dementia
Oct 12 - Blog Post: An Alert, Well-Hydrated Artist in No Acute Distress
Oct 7 - This month, a brain surgery will be broadcast on live TV for the first time ever
Oct 2 - A New Attack on Parkinson's Disease
Oct 2 - Antipsychotics for Parkinson's Psychosis May Be Dangerous
Sep 27 - The beginning of the end? The race for a Parkinson’s cure
Sep 23 - Scientists map Parkinson's spread in brain
Sep 22 - Understanding Parkinson's Disease: An Interview with Jon Palfreman
Sep 22 - Living with Lewy Body Dementia
Sep 21 - Adults with autism likely to develop Parkinson’s disease, says study
Sep 16 - Everyday activity more beneficial than occasional strenuous exercise for Parkinson’s disease
Sep 14 - UNC scientists create smarter immune cells to treat Parkinson's disease
Sep 9 - A newly discovered brain disease may point to something disturbing about Alzheimer’s and Parkinson’s
Sep 7 - Treatment for Parkinson's could replace surgery
Sep 4 - Asthma May Influence Risk of Parkinson's Disease
Sep 4 - Researchers Explore Memory Problems Related to Parkinson's
Sep 3 - Press Release: ACADIA Pharmaceuticals Submits New Drug Application for NUPLAZID™ for the Treatment of Parkinson’s Disease Psychosis
Aug 28 - Brain cells 'burn out' in Parkinson's disease
Aug 24 - Study Details Process Involved in Parkinson’s Disease
Aug 24 - Google Reveals Gigantic Ambitions To Fight Cancer, Diabetes, Parkinson's, Heart Problems